Marino-Vázquez LA, Ramírez JB, González N, Alberú J, Morales-Buenrostro LE

Language: Spanish
References: 11
Page: 86-89
PDF size: 275.06 Kb.

ABSTRACT

Introduction: The soluble fraction of CD30 (sCD30) is a molecule expressed in the cellular surface of the CD4+ T-lymphocytes, and member of the family «tumor necrosis factor/nerve growth factor (TNF/NGF)» and used like marker of risk for renal graft lost. This work evaluates its impact on survival and function of the renal graft. Patients and methods: Prospective cohort that included 70 patients who were transplanted between Jan/02-Nov/03. Sera samples were taken before kidney transplant and 2 to 6 times within the first year of post-transplant follow-up. The sCD30 and anti-HLA antibodies were measured by Elisa in the University of Heidelberg, Germany. We analyze the proportion of acute rejection, graft survival, and renal function (measured by SCr and eGFR by MDRD). Results: The age average was 33.5 ± 11.9 years, 60% men, 60% haploidentical with their donor. The 45.7% (32) were sCD30 positive, of which 28 became negative post-transplant. The 54.3% were negative before transplant, of them, 8 became positive during the first year of follow-up. The presence of sCD30 did not modify the frequency of acute rejections, the graft survival nor the renal function. Conclusion: In the kidney transplant recipients evaluated, the presence of sCD30 before transplantation was not a marker of bad outcome for the renal graft.

REFERENCES

1. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol. 2003; 10 (4): 267-271.

2. Pelzl S, Opelz G, Wiesel M et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation. 2002; 73 (1): 3-6.

3. Sengul S, Keven K, Gormez U, Kutlay S, Erturk S, Erbay B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation. 2006; 81 (8): 1216-1219.

4. Matinlauri IH, Kyllönen LE, Salmela KT, Helin H, Pelzl S, Süsal C. Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations. Transplantation. 2005; 80 (12): 1809-1812.

5. Rajakariar R, Jivanji N, Varagunam M et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant. 2005; 5 (8): 1922-1925.

6. Heinemann FM, Rebmann V, Witzke O, Philipp T, Broelsch CE, Grosse-Wilde H. Association of elevated pretransplant sCD30 levels with graft loss in 206 patients treated with modern immunosuppressive therapies after renal transplantation. Transplantation. 2007; 83 (6): 706-711.

7. Delgado JC, Pavlov IY, Shihab FS. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study. Transpl Immunol. 2009; 22 (1-2): 1-4.

8. Kim MS, Kim HJ, Kim SI et al. Pretransplant soluble CD30 level has limited effect on acute rejection, but affects graft function in living donor kidney transplantation. Transplantation. 2006; 82 (12): 1602-1605.

9. Matinlauri I, Höckerstedt K, Isoniemi H. High serum soluble CD30 does not predict acute rejection in liver transplant patients. Transplant Proc. 2006; 38 (10): 3601-3604.

10. Kwakkel-van Erp JM, Otten HG, Paantjens AW et al. Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen. J Heart Lung Transplant. 2008; 27 (10): 1172-1175.

11. Ypsilantis E, Key T, Bradley JA et al. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome. J Heart Lung Transplant. 2009; 28 (11): 1206-1210.